Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Devesh Radhakrishnan"'
Publikováno v:
Antibodies, Vol 7, Iss 1, p 1 (2017)
In order to meet desired drug product quality targets, the glycosylation profile of biotherapeutics such as monoclonal antibodies (mAbs) must be maintained consistently during manufacturing. Achieving consistent glycan distribution profiles requires
Externí odkaz:
https://doaj.org/article/9d23206bae0a4559b3e4140477a89929
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e87973 (2014)
To function as intended in vivo, a majority of biopharmaceuticals require specific glycan distributions. However, achieving a precise glycan distribution during manufacturing can be challenging because glycosylation is a non-template driven cellular
Externí odkaz:
https://doaj.org/article/33ccad1db56e4b8bbb6af67a9d6ca441
Publikováno v:
Current Opinion in Chemical Engineering. 22:81-88
The production of commercially valuable biotherapeutic molecules in mammalian systems has expanded significantly in the last thirty years, but growing economic pressures within the industry are driving efforts to reduce costs and enhance process yiel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3703e080ad39bf8bc541124a2b30a78b
https://doi.org/10.1016/j.coche.2018.09.005
https://doi.org/10.1016/j.coche.2018.09.005
Autor:
Janice Fernandez, Anne S. Robinson, Bill Meyer, Devesh Radhakrishnan, Babatunde A. Ogunnaike, Melissa M. St. Amand, James Hayes
Publikováno v:
Biotechnology Progress. 32:1149-1162
Glycan distribution has been identified as a "critical quality attribute" for many biopharmaceutical products, including monoclonal antibodies. Consequently, determining quantitatively how process variables affect glycan distribution is important dur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f665b44ab6e653aa0b521e0c37eb8714
https://doi.org/10.1002/btpr.2316
https://doi.org/10.1002/btpr.2316
Publikováno v:
Biotechnology and Bioengineering. 111:1957-1970
N-linked glycan distribution affects important end-use characteristics such as the bioactivity and efficacy of many therapeutic proteins, (including monoclonal antibodies), in vivo. Yet, obtaining desired glycan distributions consistently during batc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c5ef6481ecbb56451ebb2216d9794c4
https://doi.org/10.1002/bit.25251
https://doi.org/10.1002/bit.25251
Publikováno v:
Systems and Synthetic Biology. 4:281-291
Elementary flux mode (EFM) analysis is a powerful tool to represent the metabolic network structure and can be further utilized for flux analysis. The method enables characterization and quantification of feasible phenotypes in microbes. EFM analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c72ade83c38c2a04ab0c8617d6330876
https://doi.org/10.1007/s11693-011-9073-8
https://doi.org/10.1007/s11693-011-9073-8
Publikováno v:
Antibodies; Volume 7; Issue 1; Pages: 1
Antibodies, Vol 7, Iss 1, p 1 (2017)
Antibodies
Antibodies, Vol 7, Iss 1, p 1 (2017)
Antibodies
In order to meet desired drug product quality targets, the glycosylation profile of biotherapeutics such as monoclonal antibodies (mAbs) must be maintained consistently during manufacturing. Achieving consistent glycan distribution profiles requires
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::382f0874f8cab8d34beb9075051c9c55
https://doi.org/10.3390/antib7010001
https://doi.org/10.3390/antib7010001
Publikováno v:
Biotechnology and bioengineering. 111(10)
N-linked glycan distribution affects important end-use characteristics such as the bioactivity and efficacy of many therapeutic proteins, (including monoclonal antibodies), in vivo. Yet, obtaining desired glycan distributions consistently during batc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::368dd28cd626af51f0ea375d242bc30e
https://pubmed.ncbi.nlm.nih.gov/24728980
https://pubmed.ncbi.nlm.nih.gov/24728980
Autor:
Kevin Tran, Anne S. Robinson, Devesh Radhakrishnan, Babatunde A. Ogunnaike, Melissa M. St. Amand
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e87973 (2014)
PLoS ONE
PLoS ONE
To function as intended in vivo, a majority of biopharmaceuticals require specific glycan distributions. However, achieving a precise glycan distribution during manufacturing can be challenging because glycosylation is a non-template driven cellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f329de7592d03b6aa71b7164e5c788d5
http://europepmc.org/articles/PMC3912168?pdf=render
http://europepmc.org/articles/PMC3912168?pdf=render